Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
27.06.2023 13:13:06
|
FDA Accepts Pfizer's BLA For Fidanacogene Elaparvovec To Treat Hemophilia B
(RTTNews) - Pfizer Inc. (PFE) on Tuesday said the Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for its investigational gene therapy fidanacogene elaparvovec to treat adults with hemophilia B.
A decision from the FDA is expected in the second quarter of 2024.
Fidanacogene elaparvovec has been granted Breakthrough, Regenerative Medicines Advanced Therapy (RMAT) and orphan drug designations by the FDA, the company said.
The drug is also under review by the by the European Medicines Agency.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
14.04.25 | Pfizer Buy | Jefferies & Company Inc. | |
14.04.25 | Pfizer Neutral | UBS AG | |
14.04.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
08.04.25 | Pfizer Buy | Jefferies & Company Inc. | |
04.04.25 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 20,00 | 1,88% |
|